Tortugas Neuroscience and Korsana Biosciences emerged with significant funding to advance clinical-stage pipelines targeting neurological and neurodegenerative diseases. Tortugas raised $106 million, while Korsana secured $175 million to develop therapies for conditions including Alzheimer's, schizophrenia, and epilepsy.
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07656857 |
High-density Flexible μECoG for Epilepsy Surgery - A Single-Arm ECT |
RECRUITING | NA |
| NCT07594119 |
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures |
RECRUITING | PHASE3 |
| NCT07563881 |
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 |
RECRUITING | PHASE3 |
| NCT07505004 |
Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06309966 |
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT05794295 |
Sleep Architecture & Cognition in Focal Epilepsy |
RECRUITING | NA |
| NCT05718817 |
An Open-label Study of XEN1101 in Epilepsy |
ENROLLING_BY_INVITATION | PHASE3 |
